Meaningful Use Disclosure & Price Transparency Statement

On Nov 8, 2022,  EproSystem Inc. announced EproMedical Version 3.0.0  is compliant with the ONC criteria and was certified for healthcare IT modules by the SLI Compliance, an ONC-ACB, in accordance with the applicable Eligible Provider certification criteria adopted by the Secretary of Health and Human Services. Our certification ID is 15.02.05.1449.EPRO.02.02.1.221108 and our certification date was on Nov 8, 2022.

EproMedical V3.0.0 meets the Health IT Modules certification criteria as an integrated bundle of EHR modular products.

This Health IT Module is compliant with the ONC Certification Criteria for Health IT and has been certified by an ONC-ACB in accordance with the applicable certification criteria adopted by the Secretary of Health and Human Services. This certification does not represent an endorsement by the U.S. Department of Health and Human Services.

The additional software EproSystem Inc. relied upon to demonstrate compliance, includes Drug Information Technologies Inc., EMR Direct phiMail, EMR Direct interoperability Engine, and Surescripts.

The additional types of costs that an eligible provider would pay to implement EproMedical 3.0.0 in order to attempt to meet meaningful use objectives and measures include:

• Implementation & Hosting Costs for:
  • Cloud-based solution: Eprosystem Inc. offers a Cloud-based solution that includes hosting and implementation fees for a monthly fee; cost is per provider.
  • License-based solution: Eprosystem Inc. offers a license-based solution for a one-time software license fee per provider with additional fees for implementation. Additionally, there is a supplemental monthly support & maintenance cost; cost is per User. For license-based solution, hosting can be the responsibility of the customer or Eprosystem Inc. for a monthly fee per User.

• Subscription-based solution: Eprosystem Inc. offers a subscription based solution that includes implementation fees for a monthly fee; cost is per provider. Software will be hosted byclient.

On top of the implementation & possible hosting costs, this certified product-version could require additional costs for:

Additional costs that may be incurred for this certified product-version:

• Depending on the customer’s selected lab/imaging company & their current transactional volume, this certified product-version may require one-time costs to establish interfaces to electronically exchange results.
• This certified product-version may require a monthly charge to set up DIT service.  DIT is a third party vendor that Eprosystem Inc. uses for our medication search function.  DIT (Drug Information Technologies Inc.)
• This certified product-version may require one time cost and/or re-occurring costs to establish interfaces for reporting to immunization public health agencies or any specialized registry.
• Generating and/or transmitting QRDA Clinical Quality measures – Electronic Submission) or other format file(s) required for participation in payer quality initiatives/programs may require one-time costs, ongoing service fees, and/or transaction-based fees.
• Connecting to providers on other HISPs which are part of the Direct Trust Bundle may require ongoing service fees per provider.  Transitions of care – receive, display and incorporate transition of care/referral summaries  – Transitions of care – create and transmit transition of care/referral summaries.
• Depending on the customer’s needs, there may be costs for any additional services outside the standard agreement (such as additional implementation services, business analysis services, additional training services, etc.).

Certification Criteria to which each EHR module was Tested and Certified:

Clinical Criteria

(MU) 170.315(a)(1) – Computerized provider order entry – medications

(MU) 170.315(a)(2) – Computerized provider order entry – laboratory

(MU) 170.315(a)(3) – Computerized provider order entry – diagnostic imaging

(MU) 170.315(a)(4) – Drug-drug, drug-allergy interaction checks for CPOE

(MU) 170.315(a)(5) – Demographics

(MU) 170.315(a)(9) – Clinical Decision Support

(MU) 170.315(a)(12) – Family Health History

(MU) 170.315(a)(14) – Implantable Device List

(MU) 170.315(a)(15) – Social, psychological, and behavioral determinants data

Care Coordination

(MU) 170.315(b)(1) – Transitions of Care

(MU) 170.315(b)(2) – Clinical Information Reconciliation and Incorporation

(MU) 170.315(b)(3) – Electronic Prescribing

(MU) 170.315(b)(10) – Electronic Health Information export

Clinical Quality Measures

(MU) 170.315(c)(1) – Clinical Quality Measures (CQMs) – Record and Export

(MU) 170.315(c)(2) – Clinical Quality Measures (CQMs) – Import and Calculate

(MU) 170.315(c)(3) – Clinical Quality Measures (CQMs) – Report

Certified Clinical Quality Measures

v6 CMS2: Preventive Care and Screening: Screening for Depression and Follow-Up Plan
v5 CMS22: Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
v5 CMS50: Closing the Referral Loop: Receipt of Specialist Report
v5 CMS62: HIV/AIDS: Medical Visit
v6 CMS65: Hypertension: Improvement in Blood Pressure
v6 CMS68: Documentation of Current Medications in the Medical Record
v5 CMS69: Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan
v6 CMS74: Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists
v5 CMS75: Children Who Have Dental Decay or Cavities
v5 CMS77: HIV/AIDS: RNA control for Patients with HIV
v4 CMS82: Maternal Depression Screening
v6 CMS90: Functional Status Assessment for Congestive Heart Failure
v5 CMS117: Childhood Immunization Status
v5 CMS122: Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%)
v5 CMS123: Diabetes: Foot Exam
v5 CMS124: Cervical Cancer Screening
v5 CMS125: Breast Cancer Screening
v5 CMS126: Use of Appropriate Medications for Asthma
v5 CMS127: Pneumococcal Vaccination Status for Older Adults
v5 CMS128: Anti-depressant Medication Management
v6 CMS129: Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients
v5 CMS130: Colorectal Cancer Screening
v5 CMS131: Diabetes: Eye Exam
v5 CMS132: Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures
v5 CMS133: Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery
v5 CMS134: Diabetes: Medical Attention for Nephropathy
v5 CMS135: Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
v6 CMS136: ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication
v5 CMS137: Initiation and Engagement of Alcohol and Other Drug Dependence Treatment
v5 CMS138: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
v5 CMS139: Falls: Screening for Future Fall Risk
v5 CMS140: Breast Cancer: Hormonal Therapy for Stage I (T1b)-IIIC Estrogen Receptor/ Progesterone Receptor (ER/PR) Positive Breast Cancer
v5 CMS141: Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients
v5 CMS142: Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care
v5 CMS143: Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
v5 CMS144: Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
v5 CMS145: Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)
v5 CMS146: Appropriate Testing for Children with Pharyngitis
v6 CMS147: Preventive Care and Screening: Influenza Immunization
v5 CMS148: Hemoglobin A1c Test for Pediatric Patients
v5 CMS149: Dementia: Cognitive Assessment
v5 CMS153: Chlamydia Screening for Women
v5 CMS154: Appropriate Treatment for Children with Upper Respiratory Infection (URI)
v5 CMS155: Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents
v5 CMS156: Use of High-Risk Medications in the Elderly
v5 CMS157: Oncology: Medical and Radiation – Pain Intensity Quantified
v5 CMS158: Pregnant women that had HBsAg testing
v5 CMS159: Depression Remission at Twelve Months
v5 CMS160: Depression Utilization of the PHQ-9 Tool
v5 CMS161: Adult Major Depressive Disorder (MDD): Suicide Risk Assessment
v5 CMS163: Diabetes: Low Density Lipoprotein (LDL-C) Control (< 100 mg/dL)
v5 CMS164: Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet
v5 CMS165: Controlling High Blood Pressure
v6 CMS166: Use of Imaging Studies for Low Back Pain
v5 CMS167: Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
v5 CMS169: Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use
v5 CMS177: Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment
v5 CMS179: ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range
v6 CMS182: Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL-C Control (<100 mg/dL)

Privacy and Security

(MU) 170.315(d)(1) – Authentication, access control, and authorization

(MU) 170.315(d)(2) – Auditable Events and Tamper-Resistance

(MU) 170.315(d)(3) – Audit Reports

(MU) 170.315(d)(4) – Amendments

(MU) 170.315(d)(5) –Automatic access time-out

(MU) 170.315(d)(6) – Emergency access

(MU) 170.315(d)(7) – End-user device encryption

(MU) 170.315(d)(8) – Integrity

(MU) 170.315(d)(9) – Trusted Connection

(MU) 170.315(d)(10) – Auditing actions on health information

(MU) 170.315(d)(11) – Accounting of disclosures

(MU) 170.315(d)(12) – Encrypt authentication credentials

(MU) 170.315(d)(13) – Multi-factor authentication

Patient Engagement

(MU) 170.315 (e)(1) – View, Download, and Transmit to 3rd Party

(MU) 170.315(e)(3) – Patient health information capture

Public Health

(MU) 170.315 (f)(1) – Transmission to Immunization Registries

 Design and Performance

(MU) 170.315(g)(2) – Automated Measure Calculation

(MU) 170.315(g)(3) – Safety Enhanced Design

(MU) 170.315(g)(4) – Quality Management System

(MU) 170.315(g)(5) – Accessibility Centered Design

(MU) 170.315(g)(6) – Consolidated CDA Creation Performance

(MU) 170.315(g)(7) – Application Access – Patient Selection

(MU) 170.315(g)(9) – Application Access – All Data Request

Transport Methods and Other Protocols

(MU) 170.315(h)(1) – Direct Project

The Physician/Clinic must sign an Eprosystem Inc.Software License & Support agreement and the term of the agreement is typically a 1 to  5-year term which may vary depending on the customer’s needs.

There may be additional agreements that an Physician/Clinic must enter with a third-party vendor (such as a clearinghouse company, lab company, etc.) depending on the customer’s needs.

* To view the listing from the Certified Health IT Product List, please visit the ONC CHPL website & search for Eprosystem Inc. under the EHR certifications.